How the Latest Non-Hodgkin Lymphoma Treatments SAVED MY LIFE | What You NEED TO KNOW

There are so many developments happening in the most common subtype of non-Hodgkin lymphoma: diffuse large B-cell lymphoma (DLBCL).

The Leukemia & Lymphoma Society (LLS) and The Patient Story bring you this discussion out the biggest blood cancer/disease conference every year where top doctors and researchers discuss the most important updates (American Society of Hematology, or ASH) which took place December 2022.

In this conversation, Robyn, a three-time DLBCL survivor, and two top lymphoma specialists, Dr. Tycel Phillips from the City of Hope and Dr. Joshua Brody from Mount Sinai, discuss the latest research and treatment options in DLBCL.

Thank you to Genmab and AbbVie for their support of our patient education program.

Full story & transcript → https://www.thepatientstory.com/medic...

Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story

Contents of this Video:
00:00 - Intro
03:42 - What is diffuse large B-cell lymphoma?
07:39 - What is the treatment for a patient who relapses in the first 6-12 months?
11:44 - Bringing up different treatment options with your hematologist-oncologist
16:54 - What is CAR T-cell therapy?
19:24 - Benefits and challenges of CAR T-cell therapy
21:16 - CAR T-cell therapy for refractory patients
21:56 - Describe bispecific antibodies
25:59 - What is the comparison between epcoritamab and glofitamab?
28:56 - Side effects from bispecific antibodies
30:02 - CAR T or bispecifics for relapsed/refractory patients?

#cancersurvivor #cancerstories #cancer #thepatientstory #dlbcl #lymsm #nonhodgkinlymphoma #lymphoma #lymphomasurvivor #lymphomaawareness #cancertreatments #cancerresearch